Informed consent is a process, not a signature on a form. It is the foundation of ethical research involving human beings, and it exists to ensure that every person who participates in a clinical study does so with a clear understanding of what the study involves, what the risks are, and that their participation is entirely their own choice. In practice, patients are often handed a thick document, given limited time to read it, and asked to sign at the bottom. This article explains what informed consent should actually look like, what regulations require it to include, and how to recognize when the process is being used correctly versus when it is being misused to market unapproved products.
TLDR: Informed consent means you receive clear, honest information about a research study’s purpose, procedures, risks, benefits, alternatives, privacy protections, and your rights before agreeing to participate. FDA and HHS regulations specify the elements that must be included by law. In regenerative medicine settings specifically, signing a consent form does not make an unapproved product safe or approved, and it does not waive your right to seek recourse if something goes wrong. Understanding this distinction helps you protect yourself in a space where legitimate research and predatory marketing sometimes look similar from the outside.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease or medical condition. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. This article explains regulatory requirements for informed consent in general educational terms and does not constitute legal advice or medical advice. Patients must discuss decisions about research participation with their own licensed healthcare professionals and may consult independent legal counsel when appropriate.
Most patients who have been through a medical procedure or signed up for a study have had the experience of being handed a stack of forms and told to sign before things get started. The consent document is usually somewhere in that stack, often dense with medical and legal language, and the expectation frequently is that you will sign it quickly and move on. In routine clinical care, this is frustrating. In research involving experimental products, it is a real problem.
The concern is especially acute in regenerative medicine, where the distance between legitimate clinical research and unregulated commercial offerings is sometimes very small on the surface. The FDA’s consumer alert on regenerative medicine products including stem cells and exosomes is explicit: many stem cell and exosome products are being marketed to patients without FDA approval, and some of the settings where this happens use the language of research, including consent forms, without the oversight infrastructure that legitimate research requires. A consent form, in those settings, is not protecting the patient. It is protecting the clinic.
This guide explains what the regulations actually require, what informed consent should feel like when it is done correctly, and what red flags to look for in regenerative medicine settings specifically. By the end, you will have a practical framework for evaluating any consent form you are asked to sign in a research or clinical research context, along with specific questions to bring to that conversation.
What Informed Consent Really Is
More Than a Form
The regulatory definition of informed consent, drawn from both the HHS guidance on informed consent and FDA regulations at 21 CFR Part 50 Subpart B, is consistent: informed consent is a process that has three required components. The person must receive adequate disclosure of information. They must actually understand what they have been told. And their decision to participate must be voluntary, meaning made without coercion, undue influence, or pressure.
None of those three requirements can be satisfied by handing someone a document and asking for a signature. The disclosure requirement means you must be told the relevant information in terms you can understand. The comprehension requirement means there must be a genuine opportunity to ask questions and have them answered honestly. The voluntariness requirement means there can be no implied penalty for declining, no suggestion that your care will be affected, and no “limited time offer” pressure tactics. The document records the outcome of this process. It is not the process itself.
Regulatory Foundations
Two parallel sets of regulations govern informed consent for research involving human subjects in the United States. HHS regulations at 45 CFR 46.116 and 46.117, which apply broadly to human subjects research, and FDA regulations at 21 CFR 50.25, which apply specifically to clinical investigations of FDA-regulated products, both contain specific required elements that must appear in every consent form for covered research. The HHS informed consent FAQ page addresses many of the practical questions about how these requirements are applied.
In regenerative medicine, both sets of rules are often relevant simultaneously. When a study is investigating a product regulated by the FDA as a drug or biologic, including most interventional stem cell and HCT/P-derived product trials, the FDA’s 21 CFR 50 requirements apply on top of the HHS human subjects framework. A consent form for such a study must satisfy both.
Why Informed Consent Matters Specifically in Regenerative Medicine
Informed consent has always been important in clinical research, but it is under particular stress in regenerative medicine for reasons worth naming directly. Many regenerative medicine products are in early-stage research, which means the risk and benefit profile is genuinely uncertain. Some providers blur the line between clinical care and clinical research, marketing investigational products as treatments while labeling the encounter as research for legal protection. And the stakes for patients who are seeking options when conventional treatments have failed can make them vulnerable to accepting less rigorous consent processes than they deserve.
The guide to clinical trials for regenerative medicine on this site covers the clinical trial framework in detail. Understanding what a real clinical trial involves is one of the most useful tools for recognizing when you are not actually in one.
The Basic Elements of Informed Consent
The Eight Core Elements
The basic elements of informed consent required by 21 CFR 50.25 and the parallel HHS provisions are specific and non-optional. Every consent form for covered research must include all of them. Paraphrased in plain language, they are as follows.
First, a clear statement that the activity described is research, along with an explanation of the study’s purpose, how long participation will last, and what procedures will be involved, identifying which ones are experimental. Second, a description of any reasonably foreseeable risks or discomforts the participant might experience. Third, a description of any potential benefits to the participant or to others, being careful to note when benefits are uncertain. Fourth, disclosure of appropriate alternative procedures or treatments that the participant could consider instead of enrolling. Fifth, an explanation of how the participant’s confidentiality will be maintained and who may have access to their records. Sixth, for research involving more than minimal risk, an explanation of whether compensation or medical treatment is available if injury occurs, and how to access it if so. Seventh, contact information for someone the participant can reach with questions about the research or about their rights as a participant. And eighth, a clear statement that participation is voluntary, that refusing to participate will not affect the person’s care or benefits, and that the participant can withdraw at any time without penalty.
The NCATS consent requirements toolkit and the NIH Collaboratory regulatory requirements overview both provide accessible context for understanding how these elements are applied in practice.
Additional Elements When Appropriate
Beyond the eight core elements, regulations also specify additional elements that must be included when applicable. These include a statement about whether the research involves risks that are currently unforeseeable. Information about circumstances under which the investigator might remove the participant without their consent. A description of any additional costs the participant might bear as a result of participation. Information about what will happen to any biospecimens collected and whether they might be used for future unspecified research.
The presence or absence of these additional elements is itself informative. A consent form for an invasive regenerative medicine intervention that says nothing about additional costs or the possibility of unexpected risks is a consent form that has not been carefully constructed.
What This Should Sound Like in Plain Language
A well-written consent section addressing purpose might read something like: “This is a research study designed to test whether a single injection of cells derived from your own fat tissue is safe for adults with moderate knee pain. Participation is not a treatment for your condition, and we cannot promise that taking part will improve your symptoms. The main purpose of this study is to evaluate safety, and you may or may not experience any personal benefit.” That is the honest, required framing. A consent section that instead describes a product as having “regenerative properties proven to improve joint health” is making an unsubstantiated marketing claim inside a document that is supposed to be a legal disclosure.
Informed Consent in Regenerative Medicine Research
When FDA Informed Consent Rules Apply
FDA informed consent regulations apply to clinical investigations of FDA-regulated products. In regenerative medicine, this includes most interventional trials studying stem cells or other cellular products as drugs or biologics, which means trials involving investigational products under an active Investigational New Drug (IND) application. The FDA’s informed consent guidance page and the detailed FDA informed consent guidance document provide the authoritative regulatory framework.
An Institutional Review Board (IRB) is an independent ethics oversight committee that reviews research protocols and consent forms to confirm they meet the regulatory requirements before any participants are enrolled. The IRB’s existence and contact information should appear in any compliant consent form for FDA-regulated research. When they are absent, that is a significant omission.
The FDA Consumer Alert and What It Tells You
The FDA has been unambiguous about the state of the regenerative medicine marketplace. The FDA consumer alert on regenerative medicine products states clearly that many stem cell and exosome products are being marketed to patients without FDA approval, that serious adverse events have occurred in patients who received such products, and that some clinics misrepresent the legal status of what they are offering. The only FDA-approved stem cell products, as the alert notes, are certain cord blood-derived products for blood and immune disorders. Other stem cell and exosome products are investigational when studied under proper research conditions, or unapproved commercial products when offered outside of properly registered clinical trials.
This matters directly to informed consent because it frames the context in which patients encounter consent forms. A consent form for an unapproved product does not change the regulatory status of that product. It does not make the product safe. It does not mean the FDA has reviewed the treatment. Signing a consent form is not the same thing as agreeing to receive an approved treatment, and no consent form can transfer the FDA’s endorsement that it does not have.
The Difference Between Real Research Consent and a Liability Shield
The most important practical distinction in regenerative medicine is between informed consent in a genuinely regulated research setting and a consent document that primarily serves to protect a clinic from liability. The differences are not subtle when you know what to look for.
In a legitimate clinical trial, the consent form explicitly states that the study is research and that participation may or may not benefit the participant. It discloses risks honestly, including unknown risks. It identifies an IRB and provides contact information for the IRB and an independent contact for participant rights questions. It explains whether the product is investigational. It does not charge participants for the investigational product itself. It matches a trial that is publicly registered on ClinicalTrials.gov with an NCT identifier.
In a setting that misuses research language, the consent form may use words like “research protocol” or “observational study” while the rest of the document reads like marketing copy for a commercial service. There may be no IRB. The “research” may be charging several thousand dollars out-of-pocket for the investigational product. There is no NCT registration number to look up. The risks section is minimal or absent. This is not research with a consent form. It is commerce with a legal document attached to it.
What Good Informed Consent Should Feel Like
The Conversation That Should Accompany the Document
A compliant informed consent process is not just about the contents of the form. It is about how the form is delivered. You should be given enough time to read the entire document before you are asked to sign anything. You should have the opportunity to ask questions and receive direct, honest answers. You should be able to bring a family member, friend, or patient advocate to the conversation. If the protocol is complex, a second meeting to complete the consent process after you have had time to think is appropriate and not unusual.
None of this should involve urgency. There is no legitimate research setting where a patient is told that they must sign the consent form today or lose their spot in a study that is designed to test safety. That pressure is a consumer protection red flag regardless of what the document says.
Features of a Well-Constructed Consent Document
Beyond the conversation, the document itself should have specific structural features. A clear statement at the beginning that this is research, not standard care. An honest and balanced description of what is unknown about the product being studied. Separate sections for standard procedures and experimental procedures, so you know what would happen to you regardless of enrollment versus what is specific to the study. A specific description of who is sponsoring the research and any conflicts of interest. A clear explanation of what costs you are responsible for and what the study covers.
Green Flags Worth Noting
Signs that a consent form is from a legitimate research process include: the form identifies a specific IRB, provides the IRB’s contact information, and notes that the IRB has reviewed and approved the protocol. The form correctly identifies the regulatory framework under which the research is being conducted. The form clearly separates what is being done for research purposes from what would be done as part of your ordinary care. The form explains how your biological samples or data will be used and whether they might be used in future unspecified research. The form includes an independent contact for questions about your rights as a research participant, separate from the research team.
Red Flags in Regenerative Medicine “Consent” Forms
When Marketing Wears the Language of Research
The most important red flag to recognize is structural: a document that uses the vocabulary of research while the substantive content is indistinguishable from a commercial service pitch. Phrases like “regenerative research protocol,” “outcomes-based study,” or “personalized cell therapy research” can sound legitimate while describing something that is not. The test is whether the consent form honestly describes research designed to answer a scientific question, with all the accountability structures real research requires, or whether it describes a commercial service that has been relabeled.
Some specific patterns worth recognizing: the form claims the product is “FDA registered” or “FDA compliant” as a substitute for disclosing that the product is investigational. The form mentions registration of the facility without clarifying that facility registration is not product approval. The costs to the participant are high and non-reimbursable for the experimental product itself, which is the opposite of how legitimate clinical trial research typically works.
Missing or Weakened Required Elements
Legally required elements that are missing, vague, or buried in a consent form are not merely a formality problem. They are a signal that the form has not been reviewed by an IRB applying 21 CFR 50 or 45 CFR 46 standards. Watch for risk sections that describe only minor side effects without acknowledging unknown long-term risks. Look for an alternatives section that is either absent or dismisses other options without genuinely explaining them. Notice whether the voluntariness statement is present and clear, or whether it is hedged in language suggesting that declining will affect your relationship with the practice.
The section addressing who to contact in case of a research-related injury, and what compensation or treatment is available, is one that legitimate research takes seriously and non-compliant settings often handle vaguely or omit.
Consent Does Not Waive Your Rights
Federal regulations prohibit informed consent documents from including what are called exculpatory clauses: language that attempts to require participants to waive their legal rights or to release investigators, sponsors, or institutions from liability for negligence. If a consent form contains language stating that by signing you release the clinic from responsibility for any injury resulting from the study, that is prohibited language. It is not enforceable, and its presence tells you something about how the form was constructed. Legitimate consent forms confirm your rights. They do not attempt to waive them.
Special Topics in Informed Consent
Data, Privacy, and Your Biospecimens
Consent forms for research involving biological samples, including tissue samples of any kind, should address what will happen to those samples clearly. This includes whether identifiable information will be stored with the sample, whether the sample might be used for future research beyond the stated study, and how data derived from your samples will be used and by whom. These requirements have become more specific over time as research involving biospecimens and identifiable data has expanded. For patients considering tissue banking as a separate process from research participation, the how banking works and adipose tissue banking guide address what the banking process involves and how data and tissue are handled in that context.
Children, Vulnerable Adults, and Representatives
When a child or a person who lacks decision-making capacity is the potential participant, a parent, guardian, or legally authorized representative typically provides permission or consent on their behalf. HHS regulations under 45 CFR 46 contain specific subparts addressing these situations, and the HHS informed consent FAQ covers many of the practical questions about how these provisions work. In regenerative medicine settings specifically, where the procedures often involve collection and administration of biological products, the additional safeguards for vulnerable populations are particularly important to confirm are in place.
When Consent Requirements Can Be Modified
IRBs have limited authority to waive or alter some informed consent requirements when certain conditions are met, such as when research involves only minimal risk and the waiver would not adversely affect the rights and welfare of subjects. These waivers are narrowly available, and the conditions for them are defined specifically in 45 CFR 46.116(d). It is worth being explicit: for invasive regenerative medicine interventions involving experimental biological products administered to patients, the conditions for a consent waiver are almost certainly not met. Any setting telling you that your consent to an invasive experimental procedure has been waived deserves direct follow-up questions about the regulatory basis for that claim.
Frequently Asked Questions
Does signing an informed consent form mean the treatment is safe or approved?
No. Signing a consent form means you have been given information about a research study and have voluntarily agreed to participate. It does not change the regulatory status of any product involved. An unapproved product is still unapproved after consent is signed. The only way a product becomes FDA-approved is through the FDA’s formal approval process, which involves submitted evidence of safety and effectiveness from controlled clinical trials. Consent is an ethical and legal process that protects participants’ rights. It is not an endorsement of the product being studied.
What is the difference between a treatment consent form and a research informed consent form?
A standard treatment consent form confirms that you have been informed about a procedure your doctor recommends for your care and that you agree to proceed. A research informed consent form, governed by FDA regulations at 21 CFR Part 50 and HHS regulations at 45 CFR 46, must additionally state explicitly that the activity is research, explain the study’s scientific purpose, describe experimental elements separately from standard care, disclose reasonably foreseeable risks, describe alternatives to participation, and confirm that participation is voluntary with no penalty for declining. The research consent form is longer, more detailed, and regulated far more specifically than a routine treatment consent. When these two types of documents look identical, something is wrong.
How can I tell if a regenerative medicine study is a real clinical trial?
Look for the study on ClinicalTrials.gov. Every legitimate interventional trial involving an FDA-regulated product should be registered there with a unique NCT identifier. The consent form you receive should reference the study’s NCT number and should identify the IRB that approved the protocol. If you cannot find the study on ClinicalTrials.gov by searching the NCT number provided, or if no NCT number is provided, those are serious concerns. See the guide to clinical trials for regenerative medicine for a fuller picture of what legitimate trial participation involves.
Can a clinic charge me to be in a research study?
Legitimate clinical trials typically do not charge participants for the investigational product itself, which is the product being studied. Study-related procedures and visits are generally covered by the trial sponsor. Some studies may not cover standard-of-care costs, but those should be clearly explained. When a consent form describes a “research protocol” and simultaneously asks you to pay several thousand dollars out-of-pocket for the experimental product, that combination does not describe legitimate clinical research. It describes a commercial service using research language. The FDA’s consumer alert addresses this pattern directly.
What should I do if I feel pressured to sign a consent form quickly?
Do not sign it. A core requirement of legitimate informed consent is that it be voluntary and free from coercion or undue influence, which explicitly includes time pressure. Any consent process that presents urgency as a reason to sign quickly is failing a regulatory requirement. Ask for a copy of the document to take home. Ask for time to consult your physician. Ask for a second meeting to complete the process. If the answer to any of those requests is no, or if you are told your participation depends on signing immediately, that tells you something important about the process you are in. The FDA informed consent guidance is explicit that consent must be obtained under conditions that minimize coercion.
How is my privacy protected when I join a study?
Consent forms for covered research must explain how your identifiable information will be protected and who may have access to your records, including the sponsor, the IRB, and FDA. For research involving biological samples, the form should also address how those samples will be used and stored, whether identifiers will be removed, and whether samples may be used for future unspecified research. If you are considering banking adipose tissue, that process has its own documentation separate from research participation. The adipose-derived stem cells guide and the family banking information page on this site address those topics in their own right.
Can I change my mind after signing and withdraw from the study?
Yes. One of the eight core required elements of any informed consent form for covered research is a clear statement that participation is voluntary and that the participant may discontinue at any time without penalty or loss of benefits to which they are otherwise entitled. This right cannot be waived, and it cannot be made conditional on staying enrolled for a minimum period. Legitimate research teams understand and respect this. If you are told after enrollment that withdrawal will have consequences, that representation is inconsistent with the regulatory requirement.
Where can I learn more about informed consent requirements from official sources?
The FDA’s informed consent guidance page and the FDA detailed informed consent guidance document are the authoritative sources for FDA-regulated research. The HHS Office for Human Research Protections guidance page and the HHS informed consent FAQ cover the broader human subjects framework. The NCATS consent requirements toolkit provides a practical patient-facing resource. These are all publicly available and free to access.
How Save My Fat Thinks About Informed Consent and Education
Save My Fat’s role is tissue banking and patient education, not running interventional treatment clinics or enrolling patients in stem cell studies. The distinction is important to name directly because the regenerative medicine space is one where the line between legitimate research, banking services, and unapproved treatments is frequently blurred in marketing, and it should not be blurred here.
Save My Fat believes that informed consent and transparent education are non-negotiable foundations of any legitimate engagement in regenerative medicine.
What that means in practice for this service includes these commitments. Providing clear educational content about clinical trials, regulatory pathways, and the actual state of the science, without exaggerating the evidence or making promises about future therapies. Being honest about what tissue banking can and cannot do, including the explicit statement that banking does not guarantee access to any future trial, therapy, or clinical pathway. Following FDA and HHS guidance principles when discussing research-related topics, including directing patients to authoritative sources rather than treating our educational content as a substitute for them. And consistently encouraging patients to bring their own physician into any conversation about research participation before signing anything.
To explore these topics further, the clinical trials for regenerative medicine guide covers the structure of legitimate clinical research and how banking fits into that landscape. The emerging research page tracks active areas of adipose-derived cell science. The providers page can help patients find qualified physicians who understand both the banking process and the broader regenerative medicine context. And the about Save My Fat page describes who we are and how we operate.
No article is a substitute for a direct conversation with a licensed healthcare professional about whether any specific study, consent process, or research participation is appropriate for you. If you are uncertain about a consent form you have been asked to sign in a regenerative medicine setting, taking that form to your physician before signing it is always the right move.
This article is for educational purposes only and does not constitute legal advice or medical advice. Legal and medical review is required before publication. Please consult your licensed healthcare provider before making any decisions about research participation or clinical trial enrollment.
Last Updated: April 14, 2026
